Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Rats given continuous intravenous LPS infusion (30 mg/kg) for 4 hours to induce disseminated intravascular coagulation
- Dose used in the study
- Ultramicronised palmitoylethanolamide 30 mg/kg orally, 30 minutes before and 1 hour after the start of LPS infusion
- Duration
- 4-hour LPS infusion
- What was measured
- Coagulation markers, plasma and lung pro-inflammatory cytokines, fibrin deposition, lung damage, and mast cell numbers and serine protease release
What the authors reported
Ultramicronised palmitoylethanolamide reduced alteration of coagulation markers and pro-inflammatory cytokine release in plasma and lung caused by LPS infusion, prevented fibrin deposition and lung damage, and reduced mast cell numbers and their serine protease release.
Limits of this study
A rat model of LPS-induced coagulopathy; it cannot show effect in people with sepsis or COVID-19. One author is a coinventor on Epitech Group patents related to PEA-metabolising enzymes, described as unrelated to this study.
Source
PubMed 34768820 · doi:10.3390/ijms222111388
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.